Revolutionizing Pain Management with LASO Technology
Our Lipid modified ASO represents a paradigm shift in the field of pain management by directly disrupting nociceptive signaling, the key driver of pain perception.
This groundbreaking technology provides a powerful, non-opioid alternative to current treatments, addressing one of the most pressing challenges in pain care.
We aim at Dolinnov to ensure that pain no longer stands as a barrier to life-saving cancer treatments, such as chemotherapy, ultimately enhancing patient quality of life and treatment adherence.
Why We Must Innovate in Pain Management
Severe pain disrupts every aspect of life, from daily activities to social connections. Current treatments, especially opioids, have serious drawbacks like addiction, cognitive issues, and reduced effectiveness over time, leaving patients with few options. contributing to 600,000 deaths annually
This is especially urgent in end-of-life care, where pain deeply affects dignity and quality of life. Our mission is to create innovative solutions to address this critical need and change the future of pain management.
Precise targeting
FXYD2 is highly specific to the DRG, ensuring targeted and precise therapeutic action.
Less side effects
L-ASO technology offers greater specificity than small molecules, resulting in fewer side effects and no risk of dependency.
Outstanding preclinical Results
Validated efficacy across multiple models, including SNL, inflammatory, and Oxaliplatin-induced pain models.
How it works
New Target : FXYD2
Our research is centered on the Fxyd2 gene, which encodes the γ subunit of the Na,K-ATPase pump.
With a highly restricted expression profile, FXYD2 is prominently expressed in kidneys and specific subsets of somatosensory neurons in the dorsal root ganglia (DRG) of humans.
FXYD2 is a key protein involved in regulating neuronal hyperexcitability.
New Modality : L-ASO
The unparalleled efficacy of our L-ASO (Lipid-Antisense Oligonucleotide) technology lies in its unique and proprietary conformation.
This innovative structure enables precise targeting of nociceptive signaling pathways, ensuring exceptional effectiveness in managing severe and intractable pain.
Unlike traditional approaches of ASO, our L-ASO's novel design enhances cellular uptake and bioavailability while minimizing side effects, making it a truly disruptive solution.
Our analyses, based on NMR and circular dichroism, demonstrate that the conjugate induces a specific folding conformation.
Applications for Severe Pain Management
Chemotherapy-induced peripheral neuropathy (CIPN) is a severe complication of anticancer treatments, affecting a significant number of patients and contributing to treatment discontinuation. Platinum-based drugs, like oxaliplatin, account for approximately 47% of CIPN cases.
Current solutions are inadequate, and the unmet medical need remains substantial.
Our L-ASO technology offers a non-opioid solution for CIPN, enabling patients to undergo chemotherapy without unbearable pain and transforming cancer care.
Key Elements Strengthening Our Project
TARGET
MOA
Technology
of ROA
of DOL-001
Timeline
Discovery of Fxyd2 expression in the Peripheral Nervous System (Plos One)
Discovery of FXYD2's role in sustaining neuropathic and chronic inflammatory pain (Scientific Reports publication)
Development of a therapeutic strategy based on L-ASO technology
Optimization of the IV administration route (JCI Insight)
Dolinnov Launches with Successful First Funding Round
Initiation of Safety Studies, Dose Ranging, and Manufacturing Scale-Up.
Our Goal: Initiate a Clinical Trial as Soon as Possible.
Pipeline
We have demonstrated that DOL001, powered by our proprietary L-ASO technology, effectively addresses both neuropathic and inflammatory pain, showcasing its versatility and potential across multiple pain indications.
Product
Research
Préclinical
Phase 1
Phase 2
Phase 3
DOL-001
Chemotherapy induced peripheral
Neuropathy
DOL-001
Rare disorders
DOL-002
Non disclosed
Publications
Below, you will find the three principal publications highlighting the scientific work and advancements related to FXYD2.
